Ibrutinib use associated with high blood pressure, finds BMJ study
USA: Ibrutinib, a medication used for the treatment of certain cancers, is associated with the development of hypertension and worsening of blood pressure, a recent study has found. The researchers caution cardiologists and oncologists to be aware of this cardiotoxicity to allow timely management of BP elevations. The study findings are published in the BMJ journal Heart.Ibrutinib is a...
USA: Ibrutinib, a medication used for the treatment of certain cancers, is associated with the development of hypertension and worsening of blood pressure, a recent study has found. The researchers caution cardiologists and oncologists to be aware of this cardiotoxicity to allow timely management of BP elevations. The study findings are published in the BMJ journal Heart.
Ibrutinib is a tyrosine kinase inhibitor that is associated most commonly with atrial fibrillation. However, previous studies have identified additional cardiotoxicities including accelerated hypertension. There is no firm information on the incidence and risk factors of new or worsening hypertension following ibrutinib treatment.
Dae Hyun Lee, University of South Florida College of Medicine, Tampa, Florida, USA, and colleagues conducted a retrospective study of 144 patients diagnosed with B cell malignancies treated with ibrutinib (n=93) versus conventional chemoimmunotherapy (n=51). Their effects on blood pressure were then evaluated at 1, 2, 3, and 6 months after treatment initiation.
On analysis, the researchers found the following:
· Both treatments had similar prevalence of baseline hypertension at 63.4% and 66.7%, respectively.
· There were no differences between treatments by age, sex and baseline cardiac comorbidities.
· Both systolic and diastolic blood pressure significantly increased over time with ibrutinib compared with baseline, whereas conventional chemoimmunotherapy was not associated with significant changes in blood pressure.
· Baseline hypertensive status did not affect the degree of blood pressure change over time.
· A significant increase in systolic blood pressure (defined as more than 10 mm Hg) was noted for ibrutinib (36.6%) compared with conventional chemoimmunotherapy (7.9%) at 1 month after treatment initiation.
Despite being hypertensive at follow-up, 61.2% of patients who were treated with ibrutinib did not receive adequate blood pressure management (increase or addition of blood pressure medications).
· Within the ibrutinib group, of patients who developed more than 20 mm Hg increase in systolic blood pressure, only 52.9% had hypertension management changes.
"Ibrutinib is associated with the development of hypertension and worsening of blood pressure," wrote the authors. "Cardiologists and oncologists must be aware of this cardiotoxicity to allow timely management of blood pressure elevations."
Reference:
The study titled, "Association between ibrutinib treatment and hypertension," is published in the BMJ journal Heart.
DOI: https://heart.bmj.com/content/early/2021/06/30/heartjnl-2021-319110.full
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd